Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Entheon Biomedical Corp. (C:ENBI)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: Suite 720-999 W Broadway Street
VANCOUVER BC V5Z 1K5
Tel: N/A
Website: https://entheonbiomedical.com
IR: See website
Key People
N/A    
Business Overview
Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.
Financial Overview
For the fiscal year ended 30 November 2023, Entheon Biomedical Corp revenues increased 32% to C$250K. Net loss before extraordinary items decreased 85% to C$300K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Management, Consulting, Payroll decrease of 77% to C$303K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $0.57M as of Nov 30, 2023
Annual revenue (TTM): $0.25M as of Nov 30, 2023
EBITDA (TTM): -$0.31M as of Nov 30, 2023
Net annual income (TTM): -$0.30M as of Nov 30, 2023
Free cash flow (TTM): -$0.36M as of Nov 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 5,908,934 as of Mar 5, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization